GlassScriptPhysician profile
Matthew A Beckerdite
NPI 1821062266
$224,531.28
in general payments reported to CMS, 2019-2025
30 companies · $53K in 2025
The $53K reported for 2025 was more than what 99% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $23K · 2020: $28K · 2021: $35K · 2022: $31K · 2023: $23K · 2024: $33K · 2025: $53K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $105K · Food and Beverage: $2,088 · Travel and Lodging: $828.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $105,332.68 |
| Food and Beverage | $2,087.89 |
| Travel and Lodging | $827.57 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Takeda Pharmaceuticals U.S.A., INC. | $198,417.32 | 2020-2025 | |
| Shire North American Group INC | $22,880.04 | 2019 | |
| Abbvie INC. | $796.37 | 2020-2025 | Ubrelvy, Qulipta, Vraylar |
| Novo Nordisk INC | $426.92 | 2020-2025 | Wegovy, Ozempic, Rybelsus |
| Pfizer INC. | $415.58 | 2019-2025 | |
| Amgen INC. | $293.95 | 2019-2024 | Repatha, Otezla |
| Boehringer Ingelheim Pharmaceuticals, INC. | $253.30 | 2019-2025 | Jardiance |
| Glaxosmithkline, LLC. | $227.45 | 2021-2024 | Shingrix, Arexvy, Bexsero |
| Lilly USA, LLC | $173.95 | 2022-2024 | Mounjaro, Zepbound, Trulicity |
| Axsome Therapeutics, INC. | $114.80 | 2023 | Auvelity |
| E.R. Squibb & Sons, L.L.C. | $89.07 | 2021-2024 | Eliquis |
| Merck Sharp & Dohme LLC | $65.28 | 2020-2021 | |
| Astrazeneca Pharmaceuticals LP | $46.21 | 2023-2024 | Fasenra, Airsupra, Farxiga |
| Biohaven Pharmaceutical Holding Company LTD. | $42.05 | 2022 | |
| Currax Pharmaceuticals LLC | $29.59 | 2020-2021 |
Show all 30 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Kowa Pharmaceuticals America, INC. | $28.72 | 2020-2025 | Zoryve |
| Sanofi-Aventis U.S. LLC | $25.03 | 2020 | |
| Arbor Pharmaceuticals, INC. | $23.66 | 2020-2021 | |
| Allergan, INC. | $21.35 | 2020 | |
| Hologic Sales and Service, LLC | $19.33 | 2025 | Fluent Fluid Management System |
| Abbott Laboratories | $15.99 | 2023 | Freestyle Libre 2 |
| Exact Sciences Corporation | $15.66 | 2023 | Cologuard Collection Kit |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $14.95 | 2023 | Xifaxan |
| Phathom Pharmaceuticals, INC. | $14.74 | 2024 | Voquezna |
| Endo Pharmaceuticals INC. | $14.36 | 2020 | |
| Sanofi Pasteur INC. | $13.67 | 2019 | |
| Otsuka America Pharmaceutical, INC. | $13.28 | 2024 | Rexulti |
| Bayer Healthcare Pharmaceuticals INC. | $13.14 | 2022 | |
| Amarin Pharma, INC. | $12.86 | 2019 | |
| Janssen Pharmaceuticals, INC | $12.66 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Matthew Beckerdite listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.